Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Goodwill (2021 - 2026)

10x Genomics' Goodwill history spans 5 years, with the latest figure at $4.5 million for Q4 2025.

  • On a quarterly basis, Goodwill changed 0.0% to $4.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.5 million, a 0.0% change, with the full-year FY2025 number at $4.5 million, changed 0.0% from a year prior.
  • Goodwill hit $4.5 million in Q4 2025 for 10x Genomics, roughly flat from $4.5 million in the prior quarter.
  • Over the last five years, Goodwill for TXG hit a ceiling of $4.5 million in Q1 2021 and a floor of $4.5 million in Q1 2021.
  • Historically, Goodwill has averaged $4.5 million across 5 years, with a median of $4.5 million in 2021.
  • The widest YoY moves for Goodwill: up 0.0% in 2022, down 0.0% in 2022.
  • Tracing TXG's Goodwill over 5 years: stood at $4.5 million in 2021, then changed by 0.0% to $4.5 million in 2022, then changed by 0.0% to $4.5 million in 2023, then changed by 0.0% to $4.5 million in 2024, then changed by 0.0% to $4.5 million in 2025.
  • Business Quant data shows Goodwill for TXG at $4.5 million in Q4 2025, $4.5 million in Q3 2025, and $4.5 million in Q2 2025.